{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:26:46Z","timestamp":1793917606584,"version":"4.8.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Distinguished Scientist Fellowships Programmes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00198-025-07440-1","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T01:17:23Z","timestamp":1741223843000},"page":"951-967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0827-5303","authenticated-orcid":false,"given":"Charlotte","family":"Beaudart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jotheeswaran Amuthavalli","family":"Thiyagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bolzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Voltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Alokail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R.","family":"Fuggle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"7440_CR1","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/BF01623782","volume":"7","author":"JA Kanis","year":"1997","unstructured":"Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. The European foundation for osteoporosis and bone disease. Osteoporos Int 7:390\u2013406","journal-title":"Osteoporos Int"},{"key":"7440_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgstrom F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82","journal-title":"Arch Osteoporos"},{"key":"7440_CR3","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1007\/s40520-022-02216-7","volume":"34","author":"JA Kanis","year":"2022","unstructured":"Kanis JA, McCloskey EV, Harvey NC, Cooper C, Rizzoli R, Dawson-Hughes B, Maggi S, Reginster JY (2022) Intervention thresholds and diagnostic thresholds in the management of osteoporosis. Aging Clin Exp Res 34:3155\u20133157","journal-title":"Aging Clin Exp Res"},{"key":"7440_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40520-024-02826-3","volume":"36","author":"N Veronese","year":"2024","unstructured":"Veronese N, Briot K, Guanabens N et al (2024) Recommendations for the optimal use of bone forming agents in osteoporosis. Aging Clin Exp Res 36:167","journal-title":"Aging Clin Exp Res"},{"key":"7440_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40520-020-01708-8","volume":"33","author":"MR McClung","year":"2021","unstructured":"McClung MR (2021) Role of bone-forming agents in the management of osteoporosis. Aging Clin Exp Res 33:775\u2013791","journal-title":"Aging Clin Exp Res"},{"key":"7440_CR6","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","volume":"30","author":"J Reginster","year":"2019","unstructured":"Reginster J, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA (2019) Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int 30:1465\u20131473","journal-title":"Osteoporos Int"},{"key":"7440_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","volume":"120","author":"A Diez-Perez","year":"2019","unstructured":"Diez-Perez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodriguez M (2019) Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone 120:1\u20138","journal-title":"Bone"},{"key":"7440_CR8","doi-asserted-by":"publisher","first-page":"e24839","DOI":"10.1097\/MD.0000000000024839","volume":"100","author":"Y Ouyang","year":"2021","unstructured":"Ouyang Y, Chen S, Wan T, Zheng G, Sun G (2021) The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: a protocol for systematic review and meta-analysis. Medicine (Baltimore) 100:e24839","journal-title":"Medicine (Baltimore)"},{"key":"7440_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13018-023-03595-x","volume":"18","author":"P Hong","year":"2023","unstructured":"Hong P, Liu R, Rai S, Liu J, Zhou Y, Zheng Y, Li J (2023) Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis. J Orthop Surg Res 18:116","journal-title":"J Orthop Surg Res"},{"key":"7440_CR10","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s40520-023-02478-9","volume":"35","author":"C Beaudart","year":"2023","unstructured":"Beaudart C, Demonceau C, Sabico S, Veronese N, Cooper C, Harvey N, Fuggle N, Bruyere O, Rizzoli R, Reginster JY (2023) Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. Aging Clin Exp Res 35:1789\u20131806","journal-title":"Aging Clin Exp Res"},{"key":"7440_CR11","doi-asserted-by":"publisher","first-page":"102425","DOI":"10.1016\/j.eclinm.2024.102425","volume":"68","author":"YX Han","year":"2024","unstructured":"Han YX, Mo YY, Wu HX et al (2024) Safety and efficacy of sequential treatments for postmenopausal osteoporosis: a network meta-analysis of randomised controlled trials. EClinicalMedicine 68:102425","journal-title":"EClinicalMedicine"},{"key":"7440_CR12","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00198-023-06827-2","volume":"34","author":"RJ Moon","year":"2023","unstructured":"Moon RJ, Reginster JY, Al-Daghri NM et al (2023) Real-world evidence: new opportunities for osteoporosis research. Recommendations from a working group from the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Osteoporos Int 34:1283\u20131299","journal-title":"Osteoporos Int"},{"key":"7440_CR13","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.2106\/JBJS.19.00407","volume":"101","author":"J Bernstein","year":"2019","unstructured":"Bernstein J, Weintraub S, Morris T, Ahn J (2019) Randomized controlled trials for geriatric hip fracture are rare and underpowered: a systematic review and a call for greater collaboration. J Bone Joint Surg Am 101:e132","journal-title":"J Bone Joint Surg Am"},{"key":"7440_CR14","doi-asserted-by":"publisher","first-page":"1759720X2211050","DOI":"10.1177\/1759720X221105009","volume":"14","author":"G Adami","year":"2022","unstructured":"Adami G, Gavioli I, Rossini M, Viapiana O, Orsolini G, Benini C, Bertoldo E, Fracassi E, Gatti D, Fassio A (2022) Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study. Ther Adv Musculoskelet Dis 14:1759720X221105009","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"7440_CR15","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00198-022-06413-y","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Cooper C, Wang Y, Mitlak B, Varughese S, Williams SA (2022) Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study. Osteoporos Int 33:1703\u20131714","journal-title":"Osteoporos Int"},{"key":"7440_CR16","doi-asserted-by":"publisher","first-page":"e4222","DOI":"10.1210\/clinem\/dgac486","volume":"107","author":"T Matsumoto","year":"2022","unstructured":"Matsumoto T, Sone T, Soen S, Tanaka S, Yamashita A, Inoue T (2022) Abaloparatide increases lumbar spine and hip BMD in Japanese patients with osteoporosis: the phase 3 ACTIVE-J Study. J Clin Endocrinol Metab 107:e4222\u2013e4231","journal-title":"J Clin Endocrinol Metab"},{"key":"7440_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.eprac.2024.10.017","volume":"31","author":"L Tabatabai","year":"2024","unstructured":"Tabatabai L, Cosman F, Curtis JR et al (2024) Comparative effectiveness of abaloparatide and teriparatide in women 50 years of age and older: update of a real-world retrospective analysis. Endocr Pract 31:159\u2013168","journal-title":"Endocr Pract"},{"key":"7440_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777\u2013784","journal-title":"Ann Intern Med"},{"key":"7440_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1017\/S0266462312000086","volume":"28","author":"A Morrison","year":"2012","unstructured":"Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, Mierzwinski-Urban M, Clifford T, Hutton B, Rabb D (2012) The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care 28:138\u2013144","journal-title":"Int J Technol Assess Health Care"},{"key":"7440_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jclinepi.2021.04.012","volume":"137","author":"AI Dobrescu","year":"2021","unstructured":"Dobrescu AI, Nussbaumer-Streit B, Klerings I, Wagner G, Persad E, Sommer I, Herkner H, Gartlehner G (2021) Restricting evidence syntheses of interventions to English-language publications is a viable methodological shortcut for most medical topics: a systematic review. J Clin Epidemiol 137:209\u2013217","journal-title":"J Clin Epidemiol"},{"key":"7440_CR21","first-page":"77","volume":"2","author":"A Grey","year":"2006","unstructured":"Grey A, Reid IR (2006) Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag 2:77\u201386","journal-title":"Ther Clin Risk Manag"},{"key":"7440_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00223-013-9777-8","volume":"94","author":"T Fujita","year":"2014","unstructured":"Fujita T, Fukunaga M, Itabashi A, Tsutani K, Nakamura T (2014) Once-weekly injection of low-dose teriparatide (28.2 mug) reduced the risk of vertebral fracture in patients with primary osteoporosis. Calcif Tissue Int 94:170\u2013175","journal-title":"Calcif Tissue Int"},{"key":"7440_CR23","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"7440_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/sim.2528","volume":"26","author":"MJ Bradburn","year":"2007","unstructured":"Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26:53\u201377","journal-title":"Stat Med"},{"key":"7440_CR25","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1185\/03007995.2015.1066765","volume":"31","author":"N Boytsov","year":"2015","unstructured":"Boytsov N, Zhang X, Sugihara T, Taylor K, Swindle R (2015) Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide. Curr Med Res Opin 31:1665\u20131675","journal-title":"Curr Med Res Opin"},{"key":"7440_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11657-018-0439-3","volume":"13","author":"AA Yusuf","year":"2018","unstructured":"Yusuf AA, Cummings SR, Watts NB, Feudjo MT, Sprafka JM, Zhou J, Guo H, Balasubramanian A, Cooper C (2018) Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women. Arch Osteoporos 13:33","journal-title":"Arch Osteoporos"},{"key":"7440_CR27","doi-asserted-by":"publisher","first-page":"e12104","DOI":"10.5812\/ijem.12104","volume":"16","author":"AW Reynolds","year":"2018","unstructured":"Reynolds AW, Liu G, Kocis PT, Skowronski JN, Leslie DL, Fox EJ (2018) Comparison of osteoporosis pharmacotherapy fracture rates: analysis of a MarketScan((R)) claims database cohort. Int J Endocrinol Metab 16:e12104","journal-title":"Int J Endocrinol Metab"},{"key":"7440_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11657-022-01156-z","volume":"17","author":"J O'Kelly","year":"2022","unstructured":"O\u2019Kelly J, Bartsch R, Kossack N, Borchert J, Pignot M, Hadji P (2022) Real-world effectiveness of osteoporosis treatments in Germany. Arch Osteoporos 17:119","journal-title":"Arch Osteoporos"},{"key":"7440_CR29","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"7440_CR30","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1210\/jc.2002-020334","volume":"87","author":"JJ Body","year":"2002","unstructured":"Body JJ, Gaich GA, Scheele WH et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1\u201334)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528\u20134535","journal-title":"J Clin Endocrinol Metab"},{"key":"7440_CR31","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Zanchetta JR, Russo L et al (2012) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 23:2141\u20132150","journal-title":"Osteoporos Int"},{"key":"7440_CR32","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1210\/jc.2011-3479","volume":"97","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Sugimoto T, Nakano T et al (2012) Randomized Teriparatide [human parathyroid hormone (PTH) 1\u201334] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097\u20133106","journal-title":"J Clin Endocrinol Metab"},{"key":"7440_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3760\/cma.j.issn.0366-6999.20121626","volume":"126","author":"Y Li","year":"2013","unstructured":"Li Y, Xuan M, Wang B et al (2013) Comparison of parathyroid hormone (1\u201334) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China. Chin Med J (Engl) 126:457\u2013463","journal-title":"Chin Med J (Engl)"},{"key":"7440_CR34","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722\u2013733","journal-title":"JAMA"},{"key":"7440_CR35","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/jbmr.3067","volume":"32","author":"J Malouf-Sierra","year":"2017","unstructured":"Malouf-Sierra J, Tarantino U, Garcia-Hernandez PA et al (2017) Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture: final results of a 78-week randomized clinical trial. J Bone Miner Res 32:1040\u20131051","journal-title":"J Bone Miner Res"},{"key":"7440_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230\u2013240","journal-title":"Lancet"},{"key":"7440_CR37","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00198-021-05996-2","volume":"32","author":"H Hagino","year":"2021","unstructured":"Hagino H, Sugimoto T, Tanaka S, Sasaki K, Sone T, Nakamura T, Soen S, Mori S (2021) A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int 32:2301\u20132311","journal-title":"Osteoporos Int"},{"key":"7440_CR38","doi-asserted-by":"crossref","unstructured":"Harrison J, Mozzicato P (2009) MedDRA\u00ae: the tale of a terminology: side effects of drugs essay. Side effects of drugs annual. Elsevier, pp xxxiii-xli","DOI":"10.1016\/S0378-6080(09)03160-2"},{"key":"7440_CR39","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","volume":"350","author":"R Lindsay","year":"1997","unstructured":"Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550\u2013555","journal-title":"Lancet"},{"key":"7440_CR40","doi-asserted-by":"publisher","first-page":"e047258","DOI":"10.1136\/bmjopen-2020-047258","volume":"11","author":"CW Sing","year":"2021","unstructured":"Sing CW, Lin TC, Bartholomew S et al (2021) Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries. BMJ Open 11:e047258","journal-title":"BMJ Open"},{"key":"7440_CR41","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049\u20132102","journal-title":"Osteoporos Int"},{"key":"7440_CR42","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2949\u20132957","journal-title":"J Clin Endocrinol Metab"},{"key":"7440_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141\u2013149","journal-title":"Endocrinology"},{"key":"7440_CR44","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","volume":"5","author":"S Khosla","year":"2017","unstructured":"Khosla S, Hofbauer LC (2017) Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol 5:898\u2013907","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7440_CR45","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrendo.2015.139","volume":"11","author":"RW Cheloha","year":"2015","unstructured":"Cheloha RW, Gellman SH, Vilardaga JP, Gardella TJ (2015) PTH receptor-1 signalling-mechanistic insights and therapeutic prospects. Nat Rev Endocrinol 11:712\u2013724","journal-title":"Nat Rev Endocrinol"},{"key":"7440_CR46","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/bcp.13766","volume":"85","author":"G Tabacco","year":"2019","unstructured":"Tabacco G, Bilezikian JP (2019) Osteoanabolic and dual action drugs. Br J Clin Pharmacol 85:1084\u20131094","journal-title":"Br J Clin Pharmacol"},{"key":"7440_CR47","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00198-020-05806-1","volume":"32","author":"R Winzenrieth","year":"2021","unstructured":"Winzenrieth R, Ominsky MS, Wang Y, Humbert L, Weiss RJ (2021) Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling. Osteoporos Int 32:575\u2013583","journal-title":"Osteoporos Int"},{"key":"7440_CR48","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/j.1532-5415.2006.00695.x","volume":"54","author":"S Boonen","year":"2006","unstructured":"Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ (2006) Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 54:782\u2013789","journal-title":"J Am Geriatr Soc"},{"key":"7440_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"7440_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11657-024-01447-7","volume":"19","author":"M Li","year":"2024","unstructured":"Li M, Ge Z, Zhang B, Sun L, Wang Z, Zou T, Chen Q (2024) Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos 19:89","journal-title":"Arch Osteoporos"},{"key":"7440_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12891-019-2769-8","volume":"20","author":"YZ Jin","year":"2019","unstructured":"Jin YZ, Lee JH, Xu B, Cho M (2019) Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord 20:399","journal-title":"BMC Musculoskelet Disord"},{"key":"7440_CR52","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s00198-024-07255-6","volume":"35","author":"S Masuda","year":"2024","unstructured":"Masuda S, Fukasawa T, Matsuda S, Yoshida S, Kawakami K (2024) Comparative effectiveness and cardiovascular safety of romosozumab versus teriparatide in patients with osteoporosis: a population-based cohort study. Osteoporos Int 35:2165\u20132174","journal-title":"Osteoporos Int"},{"key":"7440_CR53","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1159\/000453138","volume":"40","author":"XC Yang","year":"2016","unstructured":"Yang XC, Deng ZH, Wen T, Luo W, Xiao WF, Zhao RB, Li YS (2016) Network meta-analysis of pharmacological agents for osteoporosis treatment and fracture prevention. Cell Physiol Biochem 40:781\u2013795","journal-title":"Cell Physiol Biochem"},{"key":"7440_CR54","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s13018-021-02678-x","volume":"16","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Maffulli N, Colarossi G, Eschweiler J, Tingart M, Betsch M (2021) Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. J Orthop Surg Res 16:533","journal-title":"J Orthop Surg Res"},{"key":"7440_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1\u201312","journal-title":"Osteoporos Int"},{"key":"7440_CR56","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00223-018-00512-x","volume":"104","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committees of Scientific A, National Societies of the International Osteoporosis (2019) Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int 104:235\u2013238","journal-title":"Calcif Tissue Int"},{"key":"7440_CR57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40520-018-1109-4","volume":"31","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committees of Scientific A, National Societies of the International Osteoporosis F (2019) Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clin Exp Res 31:15\u201317","journal-title":"Aging Clin Exp Res"},{"key":"7440_CR58","doi-asserted-by":"publisher","first-page":"564","DOI":"10.4158\/GL-2020-0524","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) American association of Clinical Endocrinologists\/American College of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis- 2020 update executive summary. Endocr Pract 26:564\u2013570","journal-title":"Endocr Pract"},{"key":"7440_CR59","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","volume":"17","author":"CL Gregson","year":"2022","unstructured":"Gregson CL, Armstrong DJ, Bowden J et al (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17:58","journal-title":"Arch Osteoporos"},{"key":"7440_CR60","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety. Toxicol Pathol 30:312\u2013321","journal-title":"Toxicol Pathol"},{"key":"7440_CR61","unstructured":"European Medicines Agency (2024) Summary of Product Characteristics \u2014 Eladynos. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eladynos-epar-product-information_en.pdf Accessed 21 Oct 2024"},{"key":"7440_CR62","unstructured":"European Medicines Agency (2024) Summary of Product Characteristics \u2014 Forsteo. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/forsteo-epar-product-information_en.pdf Accessed 30 Oct 2024"},{"key":"7440_CR63","unstructured":"Food and Drug Administration (2024) Prescribing Information \u2014 TYMLOS. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208743lbl.pdf Accessed 30 Oct 2024"},{"key":"7440_CR64","unstructured":"Food and Drug Administration (2024) Prescribing Information \u2014 FORSTEO. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/21318_forteo_lbl.pdf Accessed 30 Oct 2024"},{"key":"7440_CR65","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/01926230490462138","volume":"32","author":"JL Vahle","year":"2004","unstructured":"Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M (2004) Bone neoplasms in F344 rats given teriparatide [rhPTH(1\u201334)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426\u2013438","journal-title":"Toxicol Pathol"},{"key":"7440_CR66","first-page":"191","volume":"15","author":"AA Abdulelah","year":"2023","unstructured":"Abdulelah AA, Haddad BI, Alhajahjeh AA, AlQirem LM, El-Amayreh L (2023) The risk of developing osteosarcoma after teriparatide use: a systematic review. Orthop Res Rev 15:191\u2013198","journal-title":"Orthop Res Rev"},{"key":"7440_CR67","unstructured":"European Medicines Agency (2024) Forsteo \u2014 EPAR Procedural steps taken and scientific information after authorisation. https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/forsteo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf Accessed 19 Nov 2024"},{"key":"7440_CR68","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1002\/jbmr.1768","volume":"27","author":"EB Andrews","year":"2012","unstructured":"Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 27:2429\u20132437","journal-title":"J Bone Miner Res"},{"key":"7440_CR69","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/jbmr.4188","volume":"36","author":"A Gilsenan","year":"2021","unstructured":"Gilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB (2021) Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res 36:244\u2013251","journal-title":"J Bone Miner Res"},{"key":"7440_CR70","doi-asserted-by":"publisher","first-page":"A196","DOI":"10.1210\/jendso\/bvab048.399","volume":"5","author":"C Sherpa","year":"2021","unstructured":"Sherpa C, Shrestha BC, Nallala D, Gabriely I (2021) Hypercalcemia in a patient treated with abaloparatide. J Endocrine Soc 5:A196\u2013A197","journal-title":"J Endocrine Soc"},{"key":"7440_CR71","doi-asserted-by":"publisher","first-page":"116610","DOI":"10.1016\/j.bone.2022.116610","volume":"167","author":"AH Seeto","year":"2023","unstructured":"Seeto AH, Tadrous M, Gebre AK, Lewis JR, Fink HA, Ebeling PR, Rodriguez AJ (2023) Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: a systematic review and Bayesian network meta-analysis. Bone 167:116610","journal-title":"Bone"}],"updated-by":[{"DOI":"10.1007\/s00198-025-07452-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000}}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07440-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07440-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07440-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:02:40Z","timestamp":1748476960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07440-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7440"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07440-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article, the order in which the authors appeared in the author list was incorrectly given as","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Charlotte Beaudart<sup>1,2<\/sup>, Nicola Veronese<sup>1,3<\/sup>, Jonathan Douxfils<sup>4,5,6<\/sup>, Jotheeswaran Amuthavalli Thiyagarajan<sup>7<\/sup>, Francesco Bolzetta<sup>8<\/sup>, Paolo Albanese<sup>8<\/sup>, Gianpaolo Voltan<sup>8<\/sup>, Majed Alokail<sup>9<\/sup>, Nicholas C. Harvey<sup>1,10<\/sup>, Nicholas R. Fuggle<sup>1,10<\/sup>, Ren\u00e9 Rizzoli<sup>1,12<\/sup>, Jean-Yves Reginster<sup>1,9<\/sup> where it should have been","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Charlotte Beaudart<sup>1,2<\/sup>, Nicola Veronese<sup>1,3<\/sup>, Jonathan Douxfils<sup>4,5,6<\/sup>, Jotheeswaran Amuthavalli Thiyagarajan<sup>7<\/sup>, Francesco Bolzetta<sup>8<\/sup>, Paolo Albanese<sup>8<\/sup>, Gianpaolo Voltan<sup>8<\/sup>, Majed Alokail<sup>9<\/sup>, Nicholas C. Harvey<sup>1,10<\/sup>, Nicholas R. Fuggle<sup>1,10<\/sup>, Olivier Bruy\u00e8re<sup>1,11<\/sup>, Ren\u00e9 Rizzoli<sup>1,12<\/sup>, Jean-Yves Reginster<sup>1,9<\/sup>.","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article the affiliation '<sup>11<\/sup> Research Unit in Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium.' for Author Olivier Bruy\u00e8re was missing.","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected.","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":12,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":13,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":14,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00198-025-07452-x","URL":"https:\/\/doi.org\/10.1007\/s00198-025-07452-x","order":15,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"C.B. reports personal speaker fees from Nutricia outside the submitted work. N.V. reports personal honoraria from IBSA, Mylan, Nestl\u00e8, and Viatris, all outside the submitted work. J.D. reports personal fees from Daiichi-Sankyo, Diagnostica Stago, Estetra, Gedeon Richter, GyneBio Pharma, Mithra Pharmaceuticals, Neuralis, Norgine, Roche, Roche Diagnostics, Technoclone, Werfen, and YHLO, all outside the submitted work. N.C.H. declares that he has received personal fees, consultancy, lecture fees, and\/or honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare, Theramex, and Internis Pharma, outside the submitted work. N.R.F. declares that he has received travel bursaries from Eli Lilly and Pfizer and speaker\u2019s fees from UCB and Viatris, outside the submitted work. R.R. declares that he has received fees as a speaker or consultant for Abiogen, Effryx, Nestl\u00e9, ObsEva, and Theramex, outside the submitted work. J-Y.R. declares that he has received consulting fees or has been on paid advisory boards for IBSA-Genevrier, Viatris, Radius Health, Rejuvenate Biomed, Celltrion, Promedius, and Theramex; received lecture fees when speaking at the invitation of the sponsor for IBSA-Genevrier, Theramex, and Viatris; and received grant support from IBSA-Genevrier, Viatris, Radius Health, and TRB, all through institutions and outside the submitted work. Other authors did not report any conflicts of interest in relation with this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}